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INTRODUCTION 
The term “prehypertension” referring to those with blood 
pressure reading of 120-139mmHg systolic and 80-89mmHg diastolic, 
was first introduced when the JNC 7 was launched at the American 
Society of Hypertension annual scientific conference in 2003. It 
evoked tremendous discussions, amongst which were many objections 
to this new terminology. It was argued that this new definition of 
“illness” would impact an individual’s employability, his life as well as 
medical insurance coverage and perhaps even labelling what was an 
otherwise healthy person into a sick one. 
 
Nevertheless, this term was introduced as part of the 
categorization of hypertension because it was recognized that there is 
still an excess cardiovascular disease (CVD) risk at levels of blood 
pressure (BP) deemed previously to be “normal” or “high-normal”. 
The rationale for this new term was to bring to the attention of doctors 
and the public the need for more strenuous efforts at prevention of 
hypertension.52 
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The prevalence of prehypertension is high and the progression to 
hypertension is also high.Prehypertension is also commonly associated 
with other CVD risk factors namely obesity, diabetes mellitus, 
dyslipidemia, and inflammatory markers, and evidence of organ 
damage for example, microalbuminuria, retinal arteriolar narrowing, 
increased carotid arterial intima-media thickness, left ventricular 
hypertrophy and coronary artery disease. 
 
 Eighty-five percent of prehypertensives have one other or more 
CVD risk factor compared to normotensives. A recent study has shown 
a reduction in the development of hypertension from prehypertension 
with the use of an angiotensin receptor blocker. Unfortunately to date, 
the impact of treatment of prehypertension on CVD outcome is still 
unknown except in those with high CVD risk like diabetes or 
established CVD,or CKD. However this does not mean that nothing 
can be done for those with prehypertension. The aim of managing 
prehypertension is to lower the BP, prevent progression to 
hypertension and to prevent BP related CVD deaths. Lifestyle changes 
can reduce BP and this by itself can lower CVD risk. Until more 
evidence about other modalities of treatment become available this is a 
sensible and cost-effective way to manage prehypertension.52 
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Several large epidemiological studies have reported that elevated 
serum uric acid level is associated with cardiovascular disease. Some 
investigators have suggested that uric acid plays a causal role in the 
development of cardiovascular disease, whereas others have concluded  
that uric acid merely reflects other concomitant risk factors, such as 
hypertension, insulin resistance, obesity, or lipid abnormality. The 
independent association of uric acid with cardiovascular disease 
appears to be stronger in persons with hypertension than in the general 
population. 
 
Microalbuminuria is associated with an increased risk of 
cardiovascular morbidity in patients with diabetes,hypertension and in 
the general population.The amount of urinary albumin excretion is 
considered to be a reflection of generalized endothelial dysfunction 
associated with a variety of risk factors.Therefore, microalbuminuria is 
a useful biological marker for the identification of people who are at 
high risk for cardiovascular events and who require more intensive 
therapy. 
 
The relationship between uric acid and microalbuminuria in 
healthy adults without other cardiovascular risk factors may help to 
clarify the role of uric acid in cardiovascular disease. In this study, we 
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observed that elevated serum uric acid level was associated with 
microalbuminuria among nondiabetic and nonhypertensive subjects 
without a history of cardiovascular disease or renal dysfunction and 
whose blood pressure was in the prehypertensive range.The 
relationship between blood pressure and blood pressure–related 
morbidity is continuous over the whole range of blood pressure. If 
hyperuricaemia has an independent association in target organ damage 
among hypertensive subjects, and perhaps in subjects with 
prehypertension, it must be linearly associated with microalbuminuria. 
Identifying this subset of prehypertensives with hyperuricaemia may 
further define their cardiovascular risk and in the future may benefit 
from blood pressure lowering therapy either by lifestyle modifications 
or even with pharmacological methods. 
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of hyperuricaemia in prehypertensive 
individuals. 
2. To study the  relationship between uric acid and 
microalbuminuria in prehypertensive adults. 
3. To study if hyperuricemia has an independent role in target 
organ damage among prehypertensive subjects, as reflected by 
microalbuminuria. 
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REVIEWOF LITERATURE  
HYPERTENSION- A BACKGROUND 
  
The phenomenon of hypertension  was first characterized at the 
turn of the past century, when Riva-Rocci developed the prototype of 
the modern sphygmomanometer and so allowed the routine 
measurement of BP.Korotkoff then perfected the sphygmomanometric 
technique by describing the sounds heard over the brachial artery as the 
pressure in the cuff is reduced. In general, the upper limits of normal 
BP in older persons have been considered to be a systolic value of 140 
mm Hg and a diastolic value of 90 mm Hg. These figures may be 
adjusted downward for younger patients to the point that readings in 
excess of 120/80 mm Hg may be considered hypertensive. 
Clinically,hypertension might be defined as that level of blood pressure 
at which institution of therapy reduces blood pressure related morbidity 
and mortality.1 
 
But population studies suggest that BP is a continuous variable, 
with no absolute dividing line between normal and abnormal values. 
This situation has resulted in an inevitable continuing debate over 
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borderline readings that focuses on whether people with such pressures 
are normal and on what, in fact, constitutes normalcy.2 
 
Risks of death and disability associated with hypertension are 
increased only in a statistical sense; a large majority of patients with 
clearly elevated BP have normal longevity and health. Thus, 
hypertension is a physical sign and  a risk factor to be assessed in 
conjunction with other physiologic and environmental factors.2 
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PREHYPERTENSION- ORIGIN AND DEFINITION  
 
The term ‘prehypertension’ was coined in 1939 in the context of 
early studies that linked high blood pressure recorded during physical 
examination for life insurance purposes to subsequent morbidity and 
mortality.60 years later, this term “prehypertension” was first 
introduced when the JNC 7 was launched at the American Society of 
Hypertension annual scientific conference in 2003.This new 
classification describes ‘people with blood pressures between 120 and 
139 mmHg systolic or between 80 and 89mmHg diastolic’. 
 
Blood pressure Classification JNC-7-2003 
 
 
 
 
 
 
 
 
 
SBP 
mm Hg 
DBP 
mm Hg 
Normal <120 and <80 
Prehypertension 120-139 or 80-89 
Stage 1 Hypertension 140-159 or 90-99 
Stage 2 Hypertension ≥ 160 or ≥100 
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The ‘new’ category between normal blood pressure and 
established hypertension includes a population at high risk for 
developing hypertension with its multifaceted complications and in 
which lifestyle modifications are needed.3 
 
CONTROVERSIES IN THE NEW CLASSIFICATION: 
KEY MESSAGES FROM JNC 7: 
Blood pressure beyond 115/75mmHg, doubles CVD risk with each 
20/10mmHg rise in BP. In 2003,the JNC 7 on hypertension unified the 
normal and high normal blood pressure categories into a single entity 
termed ‘prehypertension’. This change was based on evidence from the 
Framingham Heart Study that the chance of developing hypertension is 
higher in these “prehypertensive” patients than in those with optimal 
blood pressure(<120/80) at all ages.4 
 
The European Society of Hypertension and European Society of 
Cardiology(ESH-ESC) guidelines for the management of arterial 
hypertension consider prehypertension to be categorized into 
1.Normal blood pressure(SBP 120-129mmHg or DBP 80-84mmHg) 
2.High normal blood pressure(SBP 130-139mmHg or DBP 85-
89mmHg) 
10 
 
In 2007,ESH-ESC decided not to use the term ‘prehypertension’ for 
the following reasons 
1.Even in Framingham Heart Study, the “risk of developing 
hypertension was definitely higher in patients with high normal blood 
pressure than in those with normal blood pressure”. 
2.The word ‘prehypertension’ might create anxiety and lead to 
unnecessary consultation with the doctor. 
3.This category is a highly differentiated one in practice, with the 
extremes consisting of patients in no need of any intervention as well 
as those with a very high –risk profile such as diabetes, chronic kidney 
disease, or hyperlipidemia for whom drug treatment is required. Hence, 
IHG(International Hypertension guidelines)does not  recommend the 
use of the term ‘prehypertension’. 
 
IS PREHYPERTENSION TERMINOLOGY JUSTIFIABLE?5 
The impetus for creating the prehypertension blood pressure 
category came, at least in part, from a metaanalysis that included 
approximately 1 million individuals from 61 long term epidemiological 
studies. 
 
In the Framingham Heart study, the progression rates to 
hypertension with optimal, normal and high normal blood pressure 
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were 5%,18% and 37% for the younger age groups(35-64yrs) and 
16%,26% and 50% for the older(65 to 94yrs) over a 4 year period 
respectively.6 People with prehypertension are more likely to be 
associated with hypercholesterolemia, obesity and diabetes mellitus 
than without it. It is associated with decreased life expectancy, 
increased hospitalizations and health care costs. 
 
Increased Cardiovascular risk with prehypertension is smaller than the 
risk associated with diabetes(158% higher risk), but is greater than that 
that associated with smoking(34% higher risk).since smoking is pretty 
much unchallenged as a cardiovascular risk factor, perhaps 
prehypertension should be afforded the same acceptance. Hence, 
‘Prehypertension’ terminology is justifiable.7 
 
EPIDEMIOLOGY 
The Third National Health and Nutrition examination survey 
(NHANES)1999–2000 reported that the overall prevalence of 
prehypertension in the US was 31%, higher in men than in women, and 
was higher in obese than in normal weight persons. On the basis of the 
NHANES 2005–2006 data, an estimated 25% of the US population 
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aged 20 years or older has prehypertension, including over 32 million 
men and 21 million women. 8 
Of the few Indian studies available, study done in urban Chennai, 
2,007 people were studied  , 951 (47.4%)  had  preHTN and 696 
(34.7%) had HTN. PreHTN was found in 46.6% of the men and 49.8% 
of the women. PreHTN was prevalent in 47.4% of adults, and another 
34.7% had hypertension (Stage I, 20%, and Stage II, 14.7%). In urban 
India less than 18% of adults have normal BP of less than 120/80. 9 
 
In North India, Data of study by Yadav et al22 suggested that the 
prevalence of hypertension in the youngest age group (30-39 yr) was 
13.7 per cent and increased to a peak of 64 per cent in the age group 
60-69 yr, while prevalence of pre-hypertension was highest in the age 
group 30-39 yr that is 36%.10 
 
ETIOLOGY OF PREHYPERTENSION: 
Prehypertension is one step towards hypertension, hence the same 
factors are involved in both. 
Risk factors associated are,11 
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1.Obesity 
2.Male gender 
3.Black race  
4.Type 2 Diabetes mellitus 
5.Impaired glucose tolerance 
6.Metabolic syndrome 
7.Dyslipidaemia 
8.Smoking 
Other factors being, 
• Excess salt intake 
Mean intake: men- 4100mg  ;    women- 2750mg 
• Reduced physical activity 
• Inadequate fruits, vegetables and potassium intake. 
 
PreHTN and CAD- PATHOPHYSIOLOGY: 
Prehypertension is associated with subclinical cardiovascular disease, 
including both microvascular and macrovascular pathology.12,13 
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Accordingly, the Rotterdam study, a prospective, population based 
study with 1,900 participants found that individuals with 
prehypertension had significantly smaller arteriolar and venular 
diameters and arteriolar venular ratios than normotensive individuals, 
indicating the presence of microvascular damage.14 
 
INFLAMMATORY MARKERS: 
Elevated concentrations of C-reactive protein,Tumor necrosis factor-
alpha,oxidized LDL,gamma glutamyl amyltransferase, 
microalbuminuria and other inflammatory markers are associated with 
high normal blood pressure. 
 
Oxidative stress and PreHTN: 
In ATTICA study, of 3041 men, preHTN was found to be inversely 
correlated with TAC(total oxidant capacity). PreHTN  was found to be 
associated with 15% higher levels of Oxidized LDL when compared to 
normals and hence associated with atherosclerosis. 
 
PreHTN and Insulin resistence: 
Subjects with preHTN have clinical characteristics of the IR syndrome, 
and cannot handle oral glucose challenge as the normotensives.15 
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PreHTN and microalbuminuria: 
Microalbuminuria, an organspecific manifestation of generalized 
endothelial dysfunction, that is associated with increased risk of 
cardiovascular disease – is more common in individuals with 
prehypertension than in those with normal blood pressure. 
PreHTN and serum uric acid: 
Serum uric acid was associated with PreHTN, as in established HTN 
and Atherosclerosis in Chinese adults independent of other metabolic 
risk factors.16 
PreHTN and CKD: 
First, increases in BP over time within the prehypertensive range are 
associated with morphological changes within the kidney as well as 
the behavior of the endothelium. Second, increases in albuminuria 
parallel BP increases and can antedate development of hypertension in 
Type I diabetes.17 
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Subclinical Atherosclerosis and PreHTN: 
Individuals with prehypertension often have subclinical 
atherosclerosis, manifested by increased common carotid artery intima 
media thickness and increased calcium deposition in the coronary 
arteries.Serial observations, carried out as part of the Coronary artery 
risk Development in Young adults (CarDia)study, demonstrated that 
prehypertension, especially systolic prehypertension, before the age of 
35 was significantly associated with coronary calcium in later life, 
even after adjusting for elevations in blood pressure after 35 years of 
age, other coronary risk factors and participant characteristics.20 
 
PreHTN and Diastolic dysfunction: 
Patients with PreHTN whose night time BP do not dip by 10%(non 
dippers) have more impaired diastolic dysfunction than patients with 
PreHTN  who dip and are at higher risk of development of HTN with 
CV morbidity.21  
To summarise,the excess CVD risk in prehypertension is due to 
subclinical atherosclerosis. Prehypertensives have 
• increased coronary atherosclerosis 
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• increased carotid and brachial intima-media thickness, a surrogate for 
atherosclerosis 
• elevated C-reactive proteins (CRP) 
• elevated tumour necrosis factor-α (TNF-α) 
• elevated serum homocysteine levels 
• elevated oxidized LDLcholesterol 
• microalbuminuria which is more common in prehypertension than 
normotension 
• presence of other inflammatory markers like Interleukin, serum uric 
acid, etc 
 
TREATMENT OF PREHYPERTENSION: 
A major objective of JNC 7 in creating the prehypertensive 
classification of blood pressure was to provide a tool for the 
identification of individuals for whom early adoption of a healthy 
lifestyle could lower blood pressure and prevent progression to 
hypertension, with associated reductions in target organ damage and 
cardiovascular events. Lifestyle modifications, such as weight loss, 
dietary alterations and exercise, have been shown consistently in 
randomized,controlled trials to effectively lower blood pressure and are 
recommended for patients with prehypertension.22,23,24,25 
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Lifestyle modifications to prevent and manage hypertension 
Modification Recommendation SBP reduction 
Weight reduction 
  
Sodium intake 
 
Physical exercise  
 
 
DASH Diet  
 
 
Alcohol 
Aim for BMI 18.5-25 kg/m2  
 
<100 mmol Na/6g Nacl (1¼ tsp salt)  
 
Aerobic activity e.g. brisk walking 30-
60 mins, minimum 3x/wk  
 
Rich in fruit, vegetable and low-fat 
diary products 
 
 2 units/day in men, 1 unit/day in 
women 
5-20mmHg/10kg wt loss 
  
2-8 mmHg 
 
4-9 mmHg 
 
 
8-14 mmHg 
 
 
2-4 mmHg 
 
(DASH, Dietary Approaches to Stop Hypertenstion, SBP, systolic 
blood pressure) 
Note: For over all cardiovascular mortality reduction, stop smoking. 
The effects of implemementing  these lifestyle modifications are dose- 
and time-dependent, and could be greater for some individuals. 
 
LIFESTYLE MODIFICATIONS AND CAD: 
In the PREMIER trial individuals with prehypertension or stage 1 
hypertension were randomly assigned to receive multicomponent 
behavioral interventions with or without the DASH diet, or advice 
only.A followup study of the PREMIER trial demonstrated that 
multicomponent behavioral interventions with and without the DASH 
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diet produced significant reductions in the 10 year risk of coronary 
heart disease. 26 
 
PHARMACOLOGICAL TREATMENT: 
Treatment of prehypertensive patients with antihypertensive agents in 
addition to nonpharmacological measures has been explored in clinical 
trials like TROPHY AND PHARAO TRIALS. 
 
TROPHY TRIAL: 
The trial of Preventing Hypertension (TROPHY) study tested whether 
pharmacological treatment with the angiotensin II receptor antagonist 
Candesartan cilexetil can prevent or delay the transition from 
prehypertension to stage 1 hypertension. 48 Participants with 
prehypertension were randomly assigned to receive candesartan 
cilexetil or placebo for 2 years, followed by 2 years of placebo for all 
participants. In addition, all participants received instructions for 
lifestyle modification.  
1. Over a period of  four years, nearly two thirds of the placebo 
group developed stage 1 hypertension requiring treatment. 
2. In patients with prehypertension, 2 years of treatment with 
candesartan cilexitil 16 mg once a day: 
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• During the first 2 years, the risk of developing 
hypertension was reduced by 66.3% in the participants 
who received candesartan cilexetil compared with the 
placebo group; the magnitude of risk reduction decreased 
to 16% by year 4, but was still statistically different from 
placebo group. 
• Substantially prolonged the hypertension-free period 
throughout the trial 
• Was well tolerated; during the active treatment period 
serious adverse events in candesartan and placebo groups 
were infrequent and similar.  
 
TROPHY provided the first demonstration that pharmacological 
treatment for patients with prehypertension is safe and atleast partially 
effective in reducing the risk of incident hypertension. 
 
Even after TROPHY and PHARAO TRIALS, whether 
pharmacological management of blood pressure is a useful strategy for 
the management of prehypertension is a matter of debate. 
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Patients at high risk of cardiovascular events, such as those with 
diabetes mellitus, chronic kidney disease or coronary artery disease, 
clearly benefit from aggressive intervention, and pharmacological 
treatment should be administered to these patients if blood pressure 
exceeds 130/80 mmHg. 
 
Cardiovascular risk and possible treatment of those prehypertensives 
with nontraditional risk factors like microalbuminuria, hyperuricaemia, 
raised CRP, dyslipidaemia has not been studied extensively till now. 
This study aims to explore this missing link.  
 
MICROALBUMINURIA: 
Microalbuminuria is defined as the excretion of 30 to 300mg of 
albumin per day in urine. It is not a different form or fraction of 
albumin but just a very small amount of albumin. Albumin molecule is 
relatively small and it is often the first protein to enter the urine after 
the kidney is damaged. The table below gives the values which 
constitute microalbuminuria. 27 
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Category 24hr. 
collection 
(mg/24hr) 
Timed 
collection 
(µg/min) 
Spot collection 
Albumin Creatinine 
Ratio 
µg/mg mg/mmol 
Normal <30 <20 <30 <3.4 
Micro albuminuria >300 >200 >300 >33.9 
 
 
MECHANISMS OF MICROALBUMINURIA IN ESSENTIAL 
HYPERTENSION 
Increased UAE could be the consequence of an 
1. augmented intraglomerular capillary pressure,  
2.it could reflect the existence of intrinsic glomerular damage that 
causes changes in glomerular barrier filtration,  
 3.tubular alteration that impedes the normal reabsorption of filtered 
albumin. 
 4.may represent the renal manifestation of generalized, genetically-
conditioned vascular endothelial dysfunction that may underlie the link 
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between an increased UAE and an elevated risk for cardiovascular 
disease 31 
 
 In favor of a significant role of elevated systemic blood pressure 
facilitating the transglomerular passage of albumin is the significant 
positive correlation found between office blood pressure levels and 
UAE by most groups32,33,34.In this sense systolic blood pressure has 
been shown to be one of the most relevant determinants of 
microalbuminuria in the early stages of hypertensive disease. 35On the 
other hand, higher levels of UAE have been described in those patients 
not exhibiting a nocturnal fall in blood pressure (non-dippers), 
indicating that a greater degree of renal involvement could be present 
in this particular group of patients. 36,37 
Some recent findings support an eventual relationship between 
microalbuminuria and endothelial dysfunction in hypertension that 
includes a positive correlation of UAE and circulating von Willebrand 
Factor antigen, Factor VII hyperactivity, fibrinogen and endothelial 
cell damage.38 
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MICROALBUMINURIA AS A RISK IN ESSENTIAL 
HYPERTENSION 
 
In 1974 Parving et al reported the finding of elevated UAE 
levels in insufficiently treated essential hypertensives, which correlated 
significantly with blood pressure levels and the levels fell after blood 
pressure control.This finding has been amply confirmed and it is now 
recognized that microalbuminuria can be found in up to 40% of 
untreated hypertensive population. Prevalence of an elevated UAE 
increases with age, and with longer duration and a higher severity of 
hypertension39 
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Hypertensive target organ damage is more common in 
microalbuminuric patients. Patients with elevated UAE have higher left 
ventricular mass, a higher prevalence of hypertensive retinopathy, and 
an increased thickness and presence of plaques in the carotid artery. 
Furthermore, the presence of microalbuminuria in essential 
hypertensive patients has been interpreted as a marker of early 
intrarenal vascular dysfunction in essential hypertension .40,41 
In summary, microalbuminuria is an independent predictor of 
cardiovascular morbidity and mortality in both men and women with 
essential hypertension. This could, in turn, be facilitated by the 
frequent association of an elevated urinary albumin excretion to a 
series of alterations, such as endothelial dysfunction, insulin resistance, 
altered lipid levels, higher body mass index, increased serum uric acid 
and salt-sensitivity. All these alterations could facilitate the 
accompanying risk for atherosclerosis, and it is a likely explanation for 
such an association between UAE and the risk of coronary heart 
disease. 45 
Clustering microalbuminuria with other cardiovascular risk 
factors contributes to considering that microalbuminuria in essential 
hypertension has a genetic origin. 
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Factors that cluster with microalbuminuria: 
a. Insulin resistance 
b. Central obesity 
c. Metabolic syndrome 
d. Low levels of high density lipoprotein cholesterol 
e. High triglyceride levels 
f. Systolic hypertension 
g. Lack of nocturnal dip in blood pressure on 24 hour monitoring 
h. Salt sensitivity 
i. Endothelial dysfunction 
j. Hypercoagulability 
k. Impaired fibrinolysis 
l. Renal dysfunction 
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In conclusion, microalbuminuria seems to constitute a simple and 
accurate method to detect a hypertensive patient at a high risk for 
cardiovascular and probably renal damage. 
 
PREHYPERTENSION AND MICROALBUMINURIA: 
Prehypertension is associated with a number of nontraditional risk 
markers, all of which are associated with endothelial dysfunction, 
accelerated vascular aging, and increased CV risk. Some of these 
factors include microalbuminuria,C-reactive protein, serum tumor 
necrosis factor-α, amyloid A, endothelin-1, homocysteine, advanced 
glycation end products, and higher white blood cell counts. 46 
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Microalbuminuria—an organ-specific manifestation of 
generalized endothelial dysfunction that is associated with increased 
risk of cardiovascular disease—is more common in individuals with 
prehypertension than in those with normal blood pressure.The 
appearance of albumin in the urine is a direct result of increased 
glomerular capillary permeability and serves as a marker for increased 
vascular permeability to proteins from other organs (for example, large 
arteries, heart and brain). Factors that confer a predisposition to 
microalbumin-uria, such as inflammation, oxidative stress and 
increased blood pressure, also have a role in the pathogenesis of 
microvascular and macrovascular disease. Thus, treatments that reduce 
microalbuminuria lower the risk of cardiovascular events. 
Researchers from the Framingham Heart Study followed 1499 
people without diabetes or hypertension to see whether 
microalbuminuria might predict blood pressure progression and 
incident hypertension. 
 
After a mean of 2.9 years, 230 study subjects (15%) had 
developed hypertension, and 499 (33%) had progressed to worse BP 
categories as defined by standard guidelines. In multivariate analyses, 
the ratio of albumin to creatinine in the urine predicted incident 
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hypertension. Patients in the highest quartile of albumin/creatinine 
ratio at baseline had approximately double the risk for hypertension of 
those in the lowest quartile. 
 
To summarize,it can be hypothesized that glomerular endothelial 
dysfunction, manifested as low-level microalbuminuria, is potentially 
both a precursor of essential hypertension and an indicator of patients 
at increased risk for BP progression, cardiovascular morbidity and 
mortality . Whether measuring microalbuminuria and instituting early 
intervention can change outcomes remains to be determined. 
 
SERUM URIC ACID AND HYPERURICAEMIA: 
Hyperuricemia may be defined as a plasma (or serum) urate 
concentration >420 umol/L (7.0 mg/dL). This definition is based on 
physicochemical, epidemiologic, and disease-related criteria. 
Physicochemically, hyperuricemia is the concentration of urate in the 
blood that exceeds the solubility limits of monosodium urate in plasma, 
415 umol/L (6.8 mg/dL). In epidemiologic studies, hyperuricemia is 
defined as the mean plus 2 standard deviations of values determined 
from a randomly selected healthy population. 
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HYPERTENSION AND HYPERURICAEMIA: 
Raised serum uric acid concentrations in the blood are 
commonly encountered in essential hypertension. Although the raised 
serum uric acid and episodes of gout are occasionally attributable to 
therapy, asymptomatic hyperuricemia not infrequently precedes the 
diagnosis and treatment of essential hypertension. 
 
The hyperuricemia observed in untreated hypertension may 
reflect the decrease in renal blood flow and early hypertensive 
nephrosclerosis. Epidemiological evidence to support the contention 
that uric acid is an independent risk factor for hypertension- associated 
morbidity can be gleaned from a recent multivariate analysis of 1988-
94 data on 3900 hypertensive people from the public-use database of 
the US National Health and Nutrition Survey (NHANES III). It 
showed that raised serum uric acid was associated with significantly 
higher sex-adjusted risk of heart attack and stroke. Hypertensive 
people with raised serum uric acid had a significantly higher relative 
risk (RR) for both heart attack and stroke. The NHANES III data 
support the hypothesis that uric acid is an independent risk factor for 
hypertension-associated morbidity and mortality. 
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PROPOSED MECHANISMS OF URIC ACID MEDIATED 
HYPERTENSION: 
 
1. METABOLIC SYNDROME AND RENAL HANDLING OF 
URIC ACID: 
The renal handling of uric acid may provide a physiological clue to 
why hypertension-associated morbidity is closely linked to serum uric 
acid. It is well established that serum uric acid increases as arterial 
blood pressure rises and is associated with a reduction in renal blood 
flow. 
 
High serum uric acid concentrations may increase serum sodium 
reabsorption at nephron sites proximal to the distal tubule, and it has 
been proposed that metabolic perturbations such as hyperinsulinaemia 
may mediate some of the effects of hypertension.  
 
Hyperuricaemia may represent the culmination of a 
multimetabolic syndrome in which insulin-mediated renal 
haemodynamic abnormalities lead to hypertensive renal damage. It 
seems safe to say that hyperuricaemia in hypertension may be an early 
indicator of hypertensive cardiorenal disease, which is commonly 
associated with a multimetabolic syndrome.48 
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2.GENETIC POLYMORPHISMS: 
It is also possible that genetic polymorphisms of transporters or 
enzymes involved in uric acid metabolism affect blood 
pressure, especially in younger subjects. For example, hypertension 
has been associated with polymorphisms of xanthine 
oxidoreductase. Solute carrier family 2, member 9 (SLC2A9) is a 
newly identified fructose and uric acid transporter in which several 
genetic polymorphisms have been identified that are associated with an 
increased risk of gout. 49 
 
3.DIET-LBW-URIC ACID- HYPERTENSION: 
Excessive intake of fructose or purine-rich meats or exposure to low 
doses of lead may result in chronic hyperuricemia. Mothers with 
high uric acid levels that are the result of diet or conditions such as 
preexisting hypertension, obesity, or preeclampsia may 
transfer uric acid into the fetal circulation through the placenta, which 
may ultimately contribute to intrauterine growth retardation (IUGR) 
and a reduction in nephron number. Among babies born with a low 
nephron number, hyperuricemia may develop in childhood because of 
genetic or environmental factors. Chronic hyperuricemia would 
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stimulate the renin–angiotensin system and inhibit release of 
endothelial nitric oxide, contributing to renal vasoconstriction and 
possibly increasing blood pressure. Persistent renal vasoconstriction 
may contribute to arteriolosclerosis and the development of salt-
sensitive hypertension, even if the hyperuricemia is corrected.50 
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SERUM URIC ACID-MICROALBUMINURIA-
PREHYPERTENSION: 
Our study is based on a study done in Division of Nephrology, 
Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea(2007) where they examined the cross-sectional 
association of serum uric acid level with microalbuminuria among 
6771 subjects without diabetes or hypertension.Blood pressure was 
categorized as prehypertension (systolic blood pressure, 120 to 140 mm 
Hg or diastolic blood pressure, 80 to 90 mm Hg) and normotension 
(systolic blood pressure, <120 mm Hg and diastolic blood pressure, 
<80 mm Hg).  
Microalbuminuria was found in 4.0% of normotensive subjects 
and in 7.9% of prehypertensive subjects.Prehypertensive subjects with 
microalbuminuria had higher uric acid level than those with 
normoalbuminuria. Increased serum uric acid level was an independent 
factor for microalbuminuria in the prehypertensive group. It is well 
known that microalbuminuria is associated with an increased risk for 
cardiovascular disease and might be an easily detectable marker for 
generalized vascular dysfunction. The findings of the study suggested 
that serum uric acid level can be a strong predictor of cardiovascular 
36 
 
disease when combined with elevated blood pressure (even mildly 
elevated). Endothelial dysfunction may be a possible pathway linking 
uric acid and cardiovascular disease. 
Several studies have demonstrated that subjects with 
prehypertension are at increased cardiovascular risk and may already 
have evidence of end organ damage, such as impaired ventricular 
relaxation or microalbuminuria. However, there is no data to prove that 
pharmacological therapy in prehypertension improves outcomes. Drug 
therapy in >30% of the adult population would be prohibitively 
expensive and could cause side effects that would counteract any 
beneficial effects associated with the reduction in blood pressure. The 
Joint National Committee-7 report recommends antihypertensive drugs 
in patients with diabetes or chronic kidney disease as high-risk 
patients. This observational data imply that prehypertensive subjects 
with hyperuricemia may also be a high-risk group that could benefit 
from lowering blood pressure. 
 
 In summary, this study demonstrates a strong independent 
association between uric acid level and microalbuminuria in 
prehypertensive subjects without a history of cardiovascular disease or 
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decreased renal function. Although this particular study was unable to 
determine whether hyperuricemia has a causative effect, these findings 
suggest that hyperuricemia combined with prehypertension might be 
associated with an increased risk of cardiovascular disease. 52 
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MATERIALS AND METHODS 
SETTING: 
Outpatient clinic of Government Rajaji Hospital, Madurai 
DESIGN OF STUDY: 
Analytical-cross sectional study 
PERIOD OF STUDY: 
Six months (March 2010-October 2010) 
SAMPLE SIZE AND SELECTION OF STUDY SUBJECTS: 
Hundred prehypertensive subjects(both newly and previously 
diagnosed) attending the outpatient clinic were included in this 
Analytical cross sectional study. This study group included    males 
and     females in the age group of 20-45years. 
DETAILS OF STUDY SUBJECTS: 
Blood pressure was recorded using sphygmonometer with standard 
cuff on 2 occasions 10min apart. Patients should have refrained from 
smoking or drinking tea or coffee for atleast 30min before measuring 
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BP. The higher of the two readings was taken as patient’s blood 
pressure. 
Patients’ height and weight were measured and body mass index was 
calculated using the formula weight/height2.Waist –hip ratio was 
measured. 
Subjects with waist circumference>80cm ( females) ,>90cm 
(males)(based on IDF criteria for Metabolic syndrome) were excluded 
from the study. 
All the peripheral pulses were checked with special attention to 
femorals and carotids, to detect evidence of early atherosclerosis.An 
ocular fundus examination was done to detect hypertensive 
retinopathy. 
All the subjects had routine urine analysis (albumin,sugar and 
deposits)done. Fasting and 2 hour postprandial blood sugar, serum 
urea, creatinine and fasting lipid profile were estimated.  
GFR was estimated by the Abbreviated Modification of Diet in Renal 
Disease Study Equation, that is  
GFR (mL/min/1.73 m2) = 186 x (Pcr)-1.154 x (age)-0.203 x (0.742 if female) ,where Cr is 
creatinine and GFR expressed as ml/min/1.73m2. 
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A 12 lead electrocardiogram and chest X-ray were also taken.  
Hypertension was defined as systolic blood pressure of >140 mm Hg, 
diastolic blood pressure of >90 mm Hg, or use of antihypertensive 
drugs, including diuretics. Study subjects were classified into 1 of the 2 
nonhypertensive blood pressure categories according to the criteria of 
the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure and the International Society of 
Hypertension: Prehypertension (systolic blood pressure of 120 to 140 
mm Hg or diastolic blood pressure of 80 to 90 mm Hg) and 
Normotension (systolic blood pressure >120 mm Hg and diastolic 
blood pressure >80 mm Hg). 
All the patients were instructed to report with early morning urine 
sample for Albumin creatinine ratio measurements. Serum uric acid 
levels were measured for all patients. 
 
EXCLUSION CRITERIA: 
1.Hypertension(defined by JNC 7 criteria) 
2.Diabetes Mellitus 
3.History of Cardiovascular disease or cerebrovascular accidents 
4.Microalbuminuria detected by dipstick(trace-3+) 
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5.Febrile patients 
6.Patients with UTI 
7.Patients on ACE inhibitors 
8.Metabolic syndrome based on IDF(International Diabetes 
foundation) criteria.  
 
 
ALBUMIN TO CREATININE RATIO(ACR) ESTIMATION: 
All patients were asked to report with early morning urine sample. 
Spot urine collection was used for determination of Albumin creatinine 
ratio. 
 
MICROALBUMINURIA ESTIMATION: 
Various methods to detect microalbuminuria: 
METHOD DURATION TIME OF ASSAY 
Single radio immune diffusion (Manini 1965) 1.25mg/ml 1 day 
Electro immune assay (Laurel 1966) 5mg/1 4-6hrs 
Immuno turbidimetric assay (teppor 1982) 5mg/1 20-30min 
Radio immuno assay (Keen and 6.2mcg/1 1-2days 
42 
 
Chlouvervakis, 1963) 
ELISA (Filding 1983) 250mcg/1 12-18min 
Fluoresecent immuno assay (Chavers 1984) 500mg 4-6 hrs 
Latex agglutinates immune nephelometry 
(Vasquez 1984) 
750mcg/1 6hrs 
Immuno chemical semi quantia dipstic 
(MICRAL) 
20-300mg./1 5sec-5min 
 
In our study,modified immunoturbimetric assay known as ‘turbilatex’ 
test was used to measure microalbuminuria. 
 
Microalbumin-turbilatex is a quantitative turbidimetric test for the 
measurement of microalbumin  in human urine.  
Latex particles coated with specific antibodies,anti-human albumin are 
agglutinated when mixed with samples containing micoralbumin. The 
agglutination causes an absorbance change, dependent upon the 
microalbumin contents of the patient sample that can be quantified by 
comparison from a calibrator of known microalbumin concentration. 
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CREATININE: 
Technology: Jaffe method-Rate blanked and compensated 
Method : photometry 
 
REFERANCE VALUES: 
To define microalbuminuria in random urine specimens, we used the 
ACR cutoff  values of 30 to 300 mg/g for both men and women were 
used. Subjects with an ACR<30mg/g were defined as having 
normoalbuminuria; those with ACR >300 mg/g were defined as having 
overt proteinuria. 
 
SERUM URIC ACID ESTIMATION: 
PRINCIPLE: 
The principle for the determination of Serum Uric Levels was devised 
by Trivedi and Kabasakalian with a modified Trinder peroxidase 
method using TBHB. 
 
URIC ACID + O2 + H2O   Uricase      Allantoin + CO2 + H2O2 
H2O2 + 4- AAP + TBHB    Peroxidase    Quinoneimine + H2O 
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The intensity of chromogen (Quinoneimine) formed is proportional to 
the uric acid concentration in the sample when measured at 510 nm 
(510 -550nm). 
 
REFERANCE VALUES SERUM URIC ACID LEVELS: 
In Males : 3.4 - 7.0 mg/dl 
In females : 2.4 - 6.0 mg/dl 
Hyperuricemia was defined as serum uric acid level of >7.0mg/dl for 
men and >6.0mg/dl for women. 
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RESULTS AND OBSERVATIONS 
 
AGE DISTRIBUTION: 
A total of 100 cases between the age group of 20-45 years were 
studied. The maximum number of cases34(34%) were in the 41-45 
year category. The next large number of cases31(31%) were in the 36-
40year category, followed by 31-35yr category with 16cases,26-30yr 
category with 14 cases and 21-26yr category with least number of 
cases that is 5(5%)cases. 
 Frequency Percent 
21-25 5 5.0 
26-30 14 16.0 
31-35 16 14.0 
36-40 31 31.0 
40+ 34 34.0 
Total 100 100.0 
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SEX DISTRIBUTION AMONG PREHYPERTENSIVES: 
Sex Percent 
Male 47% 
Female 53% 
 
Among total of 100 cases studied,47% were males and 53% were 
females. 
 
BMI DISTRIBUTION: 
BMI Cat Percentage 
<18.00 1.0 
18.00 – 24.99 87.0 
25.00 – 29.99 12.0 
>30 0 
 
Of the total of 100 cases, maximum number of cases (87%) were                
in 18-24.99 category (normal). 12 cases were in 25-29.99 category 
(overweight) others were in <18 category. none were in >30(obesity). 
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SMOKING AMONG PREHYPERTENSIVES: 
   Frequency Percent 
Absent 23 48.9 
Present 24 51.1 
Total 47 100.0 
 
Among the 47 male subjects, 24(48.9%) were smokers and 23(51%) 
were non smokers. All female subjects studied were non smokers. 
ALCOHOL CONSUMPTION AMONG PREHYPERTENSIVES : 
   Frequency Percent 
Absent 31 66.0 
Present 16 34.0 
Total 47 100.0 
 
Among 47 male subjects studied, 16(34%) were alchoholics and 
31(66%) were non alchoholics. All female subjects were non 
alchoholics. 
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DISTRIBUTION OF BLOOD PRESSURE: 
Category Percent 
Normal 60 
High-normal 40 
 
1. Normal blood pressure (SBP 120-129mmHg or DBP 80-84mmHg) 
2. High normal blood pressure SBP 130-139mmHg or DBP 85-
89mmHg) 
 
Of the total 100 cases studied, 60 cases belonged to ‘normal’ category 
and 40 cases belonged to ‘high normal’ category based on The 
European Society of Hypertension and European Society of 
Cardiology (ESH-ESC) classification of prehypertension. 
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BLOOD PRESSURE AND MICROALBUMINURIA: 
 
Of the total 100 cases studied, prevalence of microalbuminuria in 
prehypertension was 37%. In the ‘normal’ blood pressure category 
(120-129mmHg systolic), prevalence of microalbuminuria was 38.3%. 
In the ‘high normal’ category (130-139mmHg systolic), prevalence of 
microalbuminuria was 35%. 
 
 
 
   
  
   
Microalbuminuria 
Total  
Absent Present 
Blood pressure  
120 - 129  
Count 37 23 60 
Percent 61.7% 38.3% 100.0% 
130-139  
Count 26 14 40 
Percent 65.0% 35.0% 100.0% 
Total  
Count 63 37 100 
Percent 63.0% 37.0% 100.0% 
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SIGNIFICANCE OF MICROALBUMINURIA IN 
PREHYPERTENSION: 
Pearson Chi-
square test 
Value Df Asymp. Sig. 
(2sided) 
Person Chi-Square .114  1                 .735 
 
Pearson Chi-square test shows asymptotic significance of 
0.735.hence, there is no correlation between microalbuminuria and 
prehypertension in our study. 
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BLOOD PRESSURE AND HYPERURICAEMIA-MALES                             
FREQUENCY TABLE 
Males <=7.00 >7.00 
120-129 15 9 24 
130-139 13 10 23 
Total 28 19 47 
 
 
PERCENTAGES 
Males  <=7.00  >7.00  
120-129  62.5  37.5  
130-139  56.5  43.5  
Total  59.6  40.4  
  
BLOOD PRESSURE AND HYPERURICAEMIA: 
Of the total 47 male subjects, 40.4%(19) had hyperuricaemia. In the 
‘normal’ blood pressure category, 37.5%(9) had hyperuricaemia. In the 
‘high normal’ blood pressure category,43.5%(10) had hyperuricaemia. 
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RELATION BETWEEN BLOOD PRESSURE AND URIC ACID: 
Pearson Chi-square test shows asymptotic significance value of 
0.676.Hence, this association seems to be due to chance and there is no 
relation between blood pressure and hyperuricaemia in males in our 
study. 
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BLOOD PRESSURE AND URIC ACID - FEMALES  
FREQUENCY TABLE 
Females <=6.00 >6.00 
120-129 23 13 36 
Freq 130-139 11 6 17 
Total 34 19 53 
 
PERCENTAGES 
Females <=6.00 >6.00 
120-129 63.9 36.1 
Percent 130-139 64.7 35.3 
Total 64.2 35.8 
 
 
BLOOD PRESSURE AND HYPERURICAEMIA-FEMALES: 
Of the total 53 female subjects studied,35.8%(19) had 
hyperuricaemia.In the ‘normal’ blood pressure category,36.1%(13) had 
hyperuricaemia.In the ‘high normal’ blood pressure category,35.3%(6) 
had hyperuricaemia. 
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RELATION BETWEEN BLOOD PRESSURE AND 
HYPERURICAEMIA: 
Pearson Chi-square test showed a asymptotic significance value of 
0.954. Hence, there is no correlation between blood pressure and 
hyperuricaemia in our study. 
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MICROALBUMINURIA AND URIC ACID-MALES: 
   <= 7.00 <7  
 
 
ACR 
Normoalbuminuria Count 20 7 27 
Percent 74.1% 25.9% 100.0% 
Microalbuminuria Count 8 12 20 
Percent 40.0% 60.0% 100.0% 
Total Count 28 19 47 
Percent 59.6% 40.4% 100.0% 
 
HYPERURICAEMIA IN PREHYPERTENSIVES WITH 
MICROALBUMINURIA-MALES: 
Of the total 47 prehypertensive subjects(males) studied 20 had 
microalbuminuria and 27 had normoalbuminuria. 
Of the total 47 prehypertensive subjects(males) studied 40.4%(19) had 
hyperuricaemia. 
Prevalence of hyperuricaemia in subjects with normoalbuminuria. 
Of the 27 prehypertensive subjects(males) with normoalbuminuria, 
25.9%(7) had hyperuricaemia. 
Prevalence of hyperuricaemia in subjects with microalbuminuria. 
Of the 20 prehypertensive subjects (males) with microalbuminuria, 
60%(12) had hyperuricaemia. 
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THE FINAL OUTCOME 
RELATION OF HYPERURICAEMIA WITH 
MICROALBUMINURIA IN PREHYPERTENSIVE SUBJECTS: 
Odd Ratio : 4.29 
   Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square  5.539
a
 1 .019 
 
Pearson Chi-square test shows that asymtotic significance value is 
0.019. 
So, the association between hyperuricaemia with an (odd ratio 4.29) 
with microalbuminuria in prehypertension (males) is significant. 
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HYPERURICAEMIA IN PREHYPERTENSIVES WITH 
MICROALBUMINURIA-FEMALES: 
   Uric Acid Total 
   <=6.00 >6 
 
 
ACR 
Normoalbuminuria Count 27 9 36 
Percent 75.0% 25.0% 100.0% 
Microalbuminuria Count 7 10 17 
Percent 41.2% 58.8% 100.0% 
Total Count 34 19 53 
Percent 64.2% 35.8% 100.0% 
Odd Ratio : 4.29 
Of the total 53 prehypertensive subjects(females) studied,36 had 
normoalbuminuria and 17 had microalbuminuria. 
Of the total 53 prehypertensive subjects(females) studied,35.8%(19) 
had hyperuricaemia. 
Prevalence of hyperuricaemia in subjects with normoalbuminuria: 
Of the total 36 prehypertensive subjects(females) with 
normoalbuminuria,25%(9) had hyperuricaemia. 
Prevalence of hyperuricaemia in subjects with microalbuminuria: 
Of the total 17 prehypertensive subjects(females) with 
microalbuminuria 58.8% had hyperuricaemia. Odd Ratio : 4.29 
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THE FINAL OUTCOME: 
RELATION OF HYPERURICAEMIA WITH 
MICROALBUMINURIA IN PREHYPERTENSIVE SUBJECTS: 
   Value df Asymp. Sig. (2-sided)
Pearson Chi-Square  
5.744
a
 1 .017 
 
Pearson Chi-square test shows that asymptotic significance 
value is 0.017. 
So, the association between hyperuricaemia with an (Odds ratio 
4.29) with microalbuminuria in prehypertension (males) is significant. 
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DISCUSSION AND COMPARATIVE ANALYSIS 
Cardiovascular disease (CVD) risk is a continuum across blood 
pressure. The term prehypertension was introduced because it is now 
recognized that blood pressure readings between what is deemed 
optimal and hypertension is associated with increased CVD risk. 
 
When JNC VII  introduced a new category of blood pressure (BP), so-
called prehypertension, for those with 120-139/80-89 mm Hg, the 
purpose of this new category was to identify the individuals with 
increased risk of cardiovascular events because of elevated blood 
pressure, an increased burden of other risk factors such as obesity, 
diabetes mellitus, dyslipidemia, and inflammatory markers, and 
evidence of organ damage for example, microalbuminuria, retinal 
arteriolar narrowing, increased carotid arterial intima-media thickness, 
left ventricular hypertrophy and coronary artery disease. More 
importantly, to define this subset of people in whom an early 
intervention can reduce the risks of developing hypertension and a 
cardiovascular event.  
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FRAMINGHAM STUDY, ATTICA STUDY, Women’s health 
initiative(WHI) study uniformly associate prehypertension with 
subclinical cardiovascular disease, including both microvascular and 
macrovascular pathology.12,13 
 
Although several studies have previously shown the association 
between hyperuricemia and microalbuminuria in hypertensive patients, 
its relationship in subjects without hypertension,especially 
prehypertension is unknown.  
 
In this study, we demonstrated the relationship between serum uric 
acid level and microalbuminuria in persons with prehypertension.  
 
In our study, a total of 100 cases between the age group of 20-45 years 
were studied. The maximum number of cases34(34%) were in the 41-
45 year category. This pattern was slightly different from the large 
scale study done by Yadav et al where prevalence of prehypertension 
was highest in the 31-39yr category(36%). 
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Comorbid conditions for cardiovascular risk in our patients included, 
• Smoking  
Among the 47 male subjects,24(48.9%) were smokers and 23(51%) 
were non smokers. All female subjects studied were non smokers. 
• Alchohol consumption: 
Among 47 male subjects studied,16(34%) were alchoholics and 
31(66%) were non alchoholics. All female subjects were non 
alchoholics. 
As studied by Norman M.Kaplan, smoking can be an independent risk 
factor for prehypertension, microalbuminuria and cardiovascular 
morbidity. Smoking by causing polycythaemia, can by itself be 
associated with hyperuricaemia. 
Study done by Sabharwal et al, showed increased prevalence of 
microalbuminuria in smokers and alchoholics, reflecting their 
cardiovascular risk. 
• BMI  
Of the total of 100 cases, maximum number of cases(87%) were in 18-
24 category(normal).12 cases were in 25-29.99 category(overweight) 
others were in <18 category. none were in >30(obesity). 
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Obesity, dyslipidemia and metabolic syndrome are factors which 
cluster with microalbuminuria and hyperuricaemia. Patients with 
metabolic syndrome were excluded from this study, as hyperuricaemia 
may represent the culmination of a multimetabolic syndrome in which 
insulin-mediated renal haemodynamic abnormalities lead to 
hypertensive renal damage. 
• Microalbuminuria in prehypertension:  
Of the total 100 cases studied, prevalence of microalbuminuria 
in prehypertension was 37%. 
It has been suggested that microalbuminuria may represent the renal 
manifestation of generalized, genetically-conditioned vascular 
endothelial dysfunction that may underlie the link between an 
increased urine albumin excretion and an elevated risk for 
cardiovascular disease. In this sense, it has been described that 
microalbuminuria is associated with a decreased size- and charge-
selectivity of the glomerular vessel wall in clinically healthy subjects, 
and is an independent marker of systemic transvascular albumin 
leakiness. Furthermore, atherosclerotic vascular disease is associated 
with renal and systemic transvascular leakiness for albumin. 
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A cross sectional study done in Renal unit, Massachusetts general 
hospital, Boston concluded that ‘High-normal BP is significantly 
associated with microalbuminuria compared with optimal BP and may 
be a biomarker of the increased cardiovascular risk observed in this 
population’(odds ratio [OR], 2.13; 95% confidence interval [CI], 1.51 
to 3.01). 
A 10-year follow-up analysis of all subjects with untreated arterial 
hypertension or borderline hypertension identified within the World 
Health Organization (WHO) Multinational Monitoring of Trends and 
Determinants in Cardiovascular Disease (MONICA) study in 
Denmark, 1983 and 1984 concluded that microalbuminuria confers a 
4-fold increased risk of ischemic heart disease among hypertensive or 
borderline hypertensive subjects. 
It is safe to conclude that microalbuminuria is a established risk factor 
for both subclinical and overt cardiovascular disease. Hence, this 
particular study utilizes microalbuminuria as a parameter to assess 
subjects at increased cardiovascular risk. 
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HYPERURICAEMIA AND PREHYPERTENSION: 
Of the total 47 male subjects,40.4%(19) had hyperuricaemia. In the 
’normal’ blood pressure category,37.5%(9) had hyperuricaemia.In the 
‘high normal’ blood pressure category,43.5%(10) had hyperuricaemia. 
Of the total 53 female subjects studied,35.8%(19) had 
hyperuricaemia.In the ‘normal’ blood pressure category,36.1%(13) had 
hyperuricaemia. In the ‘high normal’ blood pressure category,35.3%(6) 
had hyperuricaemia. 
The relationship between serum uric acid and hypertension has been 
studied extensively since 1970s. Ramsay (1979) in his study of 73 men 
with untreated hypertension had with raised serum uric acid levels 
(25%) 46. Messerli et al (1980) had an incidence of 72 % raised serum 
uric acid in their study population of 39 established 
hypertensives.Messerli and Frohlich et al hypothesized that the 
frequent presence of hyperuricemia in hypertensive patients reflects 
underlying renal dysfunction or reduced renal perfusion. 
Three possible conclusions can be drawn from the association of 
hypertension with raised serum uric acid levels. Hypertension may 
arise as a result of hyperuricemia, hypertension can cause 
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hyperuricemia and the duration and severity of hypertension is related 
directly to the Serum uric acid levels. 
But, the relationship between serum uric acid,prehypertension and its 
cardiovascular risk is almost unknown. The Korean study done in 
Samsung Medical center on which our present study is based is one of 
the few studies in this direction. 
RELATION BETWEEN HYPERURICAEMIA AND 
MICROALBUMINURIA: 
Of the 27 prehypertensive subjects (males) with 
normoalbuminuria,25.9%(7) had hyperuricaemia.Of the 20 
prehypertensive subjects(males) with microalbuminuria,60%(12) had 
hyperuricaemia.(Odds ratio 4.29) 
Of the total 36 prehypertensive subjects(females) with 
normoalbuminuria,25%(9) had hyperuricaemia.Of the total 17 
prehypertensive subjects(females) with microalbuminuria 58.8% had 
hyperuricaemia.(Odds ratio 4.29) 
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In both males and female prehypertensive subjects,those with 
microalbuminuria had higher uric acid levels than those with 
normoalbuminuria and this relation was statistically significant.(men p 
value-0.019,women p value-0.017,odds ratio 4.29) 
 
In the study done in Samsung medical center, Seoul, Korea by Jung 
Eun Lee et al, Prehypertensive subjects with microalbuminuria had 
higher uric acid level than those with normoalbuminuria (men, 387[68] 
mmol/L versus 371 [69] mmol/L; P_0.017; women 286 [56] mmol/L 
versus 262 [54] mmol/L; P_0.006). In the normotensive group, serum 
uric acid quartile did not show the independent association with 
microalbuminuria. The independent relationship between serum uric 
acid level and microalbuminuria was confirmed by the results of 
multiple logistic regression analyses . In the prehypertensive group, 
after adjustment for other cardiovascular risk factors (age, BMI, 
smoking status, serum glucose,low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol, CRP, fibrinogen, and GFR), upper 
uric acid quartiles were associated with a higher risk of 
microalbuminuria for both men (P_0.004 for trend) and women 
(P_0.025 for trend). Compared with the lowest quartile, the highest 
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uric acid quartile entailed  >2 times greater risk for microalbuminuria 
in both men (odds ratio, 2.12; 95% CI, 1.16 to 3.87) and women (odds 
ratio, 3.36; 95% CI, 1.17 to 9.69). In the normotensive group, serum 
uric acid quartile was not an independent factor for microalbuminuria.  
 
This study demonstrates a strong independent association between uric 
acid level and microalbuminuria in prehypertensive subjects without a 
history of cardiovascular disease or decreased renal function. It is well 
known that microalbuminuria is associated with an increased risk for 
cardiovascular disease and might be an easily detectable marker for 
generalized vascular dysfunction. Although we are unable to determine 
whether serum uric acid has a causative role in hypertension or 
prehypertension, the findings of the study suggest that serum uric acid 
level can be a strong predictor of cardiovascular disease when 
combined with elevated blood pressure (even mildly 
elevated).Endothelial dysfunction may be a possible pathway linking 
uric acid and cardiovascular disease.52 
 
Several studies have demonstrated that subjects with prehypertension 
are at increased cardiovascular risk and may already have evidence of 
end organ damage, such as impaired ventricular relaxation or 
microalbuminuria. However, there is no data to prove that 
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pharmacological therapy in prehypertension improves outcomes. Drug 
therapy in >30% of the adult population would be prohibitively 
expensive and could cause side effects that would counteract any 
beneficial effects associated with the reduction in blood pressure. The 
Joint National Committee-7 report recommends antihypertensive drugs 
in patients with diabetes or chronic kidney disease as high-risk 
patients. Our observational data imply that prehypertensive subjects 
with hyperuricemia may also be a high-risk group that could benefit 
from lowering blood pressure by both lifestyle modifications and 
pharmacological methods.52 
 
LIMITATIONS OF THE STUDY: 
1. This was a cross-sectional study; therefore, we were unable to 
examine the impact of hyperuricemia over time. 
2.Normotensives were not examined, hence multiple regression 
analysis could not be done to confirm the independent association 
between hyperuricaemia and cardiovascular risk in prehypertension. 
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FUTURE AREAS OF RESEARCH: 
1.Prospective studies to study the actual cardiovascular events and risk 
in prehypertensive subjects with hyperuricaemia are needed to to prove 
this association. 
2.Hyperuricaemia in prehypertension and hypertension-a cause or 
effect? 
This has to addressed by studies which may include pharmacological 
treatment of prehypertensive subjects with hyperuricaemia either with 
antihypertensives or uric acid lowering drugs. 
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CONCLUSION 
The following conclusions were derived from the study, 
1.Prehypertension clusters with other cardiovascular risk factors like 
smoking, alchoholism, dyslipidemia ,microalbuminuria and 
hyperuricaemia. 
 
2.Hyperuricaemia is an independent risk factor for microalbuminuria 
and thereby cardiovascular risk in prehypertension. 
 
3. Urinary albumin excretion rate can be used as an immediate end 
point to evaluate the outcome of lowering the uric acid level in future 
investigations, and this will help draw a conclusion regarding its 
relation with cardiovascular disease. 
 
4.As per JNC 7,pharmacological treatment is recommended for 
prehypertension, only if associated with diabetes,chronic kidney 
disease,microalbuminuria,etc ,this study suggests that the subset of 
patients with hyperuricaemia can also be regarded as a high risk group 
who could benefit from blood pressure lowering therapy. 
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SUMMARY 
This study  “CORRELATION BETWEEN SERUM URIC 
ACID AND MICROALBUMINURIA IN PREHYPERTENSION” 
was carried out in Govt. Rajaji Hospital, Madurai Medical College, 
Madurai from March 2010 to October 2010. 
100 cases of prehypertension in the age group of 20-45years 
were studied during this period.Male subjects-43% and females-57%. 
Hyperuricaemia was found to be strongly associated with 
microalbuminuria in prehypertensive subjects.  
Increased uric acid level in a prehypertensive group should be 
considered as a risk factor for cardiovascular disease. 
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